Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesRadiation Oncologymediviewcurative Radiation Therapy Policy Update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedmediviewcurativePolicy CUR-ONC-2026-001

    Radiation Therapy Policy (Coverage Criteria for EBRT, SBRT/SRS, PBT, Brachytherapy, SRT)

    Customize your policy alerts

    Sign up for mediviewcurative Policy CUR-ONC-2026-001 alerts

    Get alerted when Policy CUR-ONC-2026-001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria and coding policy governing medical necessity, prior authorization, and billing for radiation therapy services (multiple modalities) for members of Curative Health Plan in specified states and age groups.

    Policy Summary
    Payermediviewcurative
    PolicyRadiation Therapy Policy (CUR-ONC-2026-001)
    Policy CodePolicy CUR-ONC-2026-001
    Change TypeCode set and billing updates (2026 CPT/HCPCS)
    Effective DateApr 28, 2026
    Last ReviewApr 28, 2026
    Next Review DateApr 1, 2027
    Key ActionObtain prior authorization for all listed radiation therapy codes and include required documentation (diagnosis, performance status, staging, and complete physician-signed radiation prescription).
    SourceLink
    POLICY UPDATE CHANGES

    Radiation oncology delivery coding was reorganized into 2026 complexity-based codes (77402, 77407, 77412) and multiple legacy CPT/HCPCS codes were deleted or replaced.

    New Surface Radiation Therapy (SRT) codes (77436-77439) introduced with SRT-specific planning and billing guidance.

    IGRT G-codes G6001-G6017 and CPT 77014 deleted effective January 1, 2026; technical IGRT bundled into delivery codes with only professional component (77387-26) separately reportable.

    CPT 77401 (superficial/orthovoltage delivery) is deleted effective January 1, 2026 and must not be billed; new SRT CPT codes 77436-77439 established for 2026.

    CPT 77401 (superficial/orthovoltage delivery) is deleted effective January 1, 2026 and must not be billed; new 2026 SRT CPT codes 77436-77439 are defined for planning, delivery, and add‑on ultrasound guidance.

    3EBRT delivery levels
    77436-77439New SRT codes
    77387-26IGRT professional code
    TX,FL,GA,DC,MD,IN,OHApplicable states
    8Site-specific guidance entries

    Coverage Criteria and Medical Necessity

    inv-01: Universal Prerequisites

    Covered when ALL of the following are met:

    Universal Prerequisites: 1) Confirmed diagnosis of a malignant neoplasm or a specified benign condition with pathology report or equivalent clinical evidence; 2) Complete physician-signed radiation prescription including diagnosis with ICD-10 code(s), clinical stage, explicit treatment intent, and anatomic target volumes (GTV, CTV, PTV as applicable); 3) Documented performance status (KPS or ECOG); 4) Clinical staging with supporting imaging consistent with the planned treatment; 5) Clinical appropriateness of the selected radiation modality and a complete treatment plan meeting the elements in Section 4 Universal Prerequisites.

    These prerequisites apply to all modalities and age groups unless age-specific criteria elsewhere modify them.

    inv-02: Treatment Planning Codes

    Coverage is met when ALL of the following apply:

    Universal prerequisite: Confirmed malignant or specified benign diagnosis documented and meets the Universal Prerequisites in Section 4.
    Policy Summary
    Payermediviewcurative
    PolicyRadiation Therapy Policy (CUR-ONC-2026-001)
    Policy CodePolicy CUR-ONC-2026-001
    Change TypeCode set and billing updates (2026 CPT/HCPCS)
    Effective DateApr 28, 2026
    Last ReviewApr 28, 2026
    Next Review DateApr 1, 2027
    Key ActionObtain prior authorization for all listed radiation therapy codes and include required documentation (diagnosis, performance status, staging, and complete physician-signed radiation prescription).
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCPT/HCPCS and Diagnosis CodesProvider Requirements, Prior Authorization, and Billing RulesBackground and ContextDefinitions and Code-Specific NotesRevision History and Document Changes
    Complexity-consistent coding: The selected planning CPT code accurately reflects planning complexity: Simple (single area/field; codes e.g., 77261, 77280, 77306), Intermediate (two or more regions/fields; e.g., 77263, 77285, 77307), Complex (≥3 fields, special techniques, proximity to critical structures; e.g., 77262, 77290).
    Respiratory motion management (77293): Covered when target shows clinically significant respiratory motion and 4D-CT or equivalent motion-management simulation is required for IMRT, SBRT, or proton delivery to ensure target accuracy.
    IMRT planning (77301): Covered when IMRT delivery (77407 or 77412) is planned and medically indicated per IMRT indications; inverse planning performed; radiation oncologist reviews and signs DVHs for all targets and OARs.

    IMRT planning is not covered when IMRT indications in Section 4B are not met.

    Brachytherapy isodose planning: Covered for each brachytherapy implant/application with complexity matched to number of planes/channels/sources (77316 simple; 77317 intermediate; 77318 complex).
    Unlisted planning (77299): Requires individual clinical review and written justification from the radiation oncologist documenting why no established planning code applies.

    inv-03: Treatment Management Codes

    Coverage is met when the following conditions apply depending on the management code:

    Weekly treatment management (77427): One unit per 5 fractions (or weekly if receiving daily RT) with documented radiation oncologist management visit covering tolerance assessment, imaging/port film review, clinical status, and plan modifications. Not billable for SRT (see Section 4G).
    Short-course management (77431): Used for courses consisting of only 1–2 fractions or when 77427 is inappropriate.
    SRS management - complete course (77432): One unit for complete cranial SRS course with documented radiation oncologist evaluation of clinical and technical aspects and recorded management decision.

    Applies to cranial SRS only.

    Medical physics consultation (77336): Billed per 5 fractions; requires documented physicist review of treatment parameters, dosimetric accuracy, and QA. Applicable to SRT when a licensed physicist provides oversight; billable weekly per 5 SRT treatments.
    Special medical physics consultation (77370): Covered for one of listed specialized events per consultation (e.g., brachytherapy+EBRT oversight, fusion of multiple image sets by physicist, dosimetric analysis of overlapping/abutting fields, fetal or implanted-device dose analysis, SRS/SBRT dosimetric report).
    Intraoperative radiation (77469): Covered when radiation is delivered in an operating room during same-day surgical procedure with the radiation oncologist physically present.
    Special treatment procedure (77470): Covered in addition to primary delivery when one or more conditions apply (e.g., concurrent cytotoxic therapy requiring special timing, brachytherapy combined with EBRT, proton therapy, TBI/hemibody, pediatric anesthesia under 18 with daily physician supervision, reconstruction of prior plan, or other documented complex circumstances).

    inv-04: EBRT Delivery Levels

    Select delivery level based on clinical complexity; documentation must support level selection.

    Level 1 - 77402 (Simple): Applies to single electron field, multiple non-abutting electron fields, or 2D photon treatment. Expected utilization <5% of EBRT cases.
    Level 2 - 77407 (Intermediate): Applies to single isocenter 3D-CRT or IMRT without active motion management (no gating/SGRT/breath-hold/4D CBCT during delivery). Examples: standard prostate IMRT (single isocenter), whole breast, pelvic nodal IMRT. Expected utilization >50%.
    Level 3 - 77412 (Complex): Requires documentation of ANY ONE: (a) active motion management (gating, SGRT, breath-hold, 4D CBCT during delivery), (b) multiple isocenters, (c) mixed photon-electron modality, or (d) total skin electron therapy (TSET). Clinical record must include explicit qualifying phrase (e.g., 'Multiple isocenters utilized' or 'Active motion management employed') or auditors may downcode to 77407.

    Auditors may downcode Level 3 without explicit documentation.

    inv-05: 3D-CRT and Site-Specific Regimens

    3D-CRT is medically necessary when indicated per evidence-based guidelines; site-specific regimens provided.

    Breast cancer - whole breast and PMRT: WBI after breast-conserving surgery for invasive carcinoma or DCIS; preferred dose 40–42.5 Gy in 15–16 fractions (moderate hypofractionation, NCCN Category 1). Alternatives and boost dose recommendations provided; PMRT indicated for pN1–N3, T3–T4, or high-risk node-negative features. Regional nodal irradiation criteria included.
    Lung cancer: Stage III NSCLC: concurrent chemoradiotherapy 60 Gy in 30 fractions with concurrent platinum doublet; dose escalation beyond 60 Gy is not medically necessary. SCLC limited stage: concurrent thoracic RT with chemotherapy with specified fractionation; PCI for responders per guidelines.
    Prostate cancer: Definitive RT options: moderate hypofractionation 60–70 Gy in 20–28 fractions preferred; conventional 75.6–79.2 Gy acceptable. IMRT required for moderate hypofractionation with IGRT. Fraction limits and post-prostatectomy RT indications/doses provided.
    Colorectal cancer: Stage II–III rectal cancer: neoadjuvant RT recommended. Short-course 25 Gy in 5 fractions or long-course 45–50.4 Gy in 25–28 fractions with concurrent fluoropyrimidine; both acceptable within TNT protocols.
    Lymphoma: Hodgkin Stage I–II: ISRT 20–30 Gy post-chemo; unfavorable I–II: 30–36 Gy. NHL limited stage: ISRT 24–30 Gy. Indolent advanced NHL palliative: 4 Gy in 2 fractions or single 4 Gy.
    Brain/CNS: GBM: 60 Gy in 30 fractions with concurrent temozolomide (Stupp); hypofractionated 40 Gy in 15 for elderly/poor PS. Low-grade glioma 50.4–54 Gy in 28–30 fractions. WBRT 30 Gy in 10 or 37.5 Gy in 15; consider hippocampal-avoidance with memantine when feasible.
    Head and neck: IMRT is standard for all primary head and neck cancers. Palliative head and neck RT: 20–30 Gy in 5–10 fractions.

    inv-06: IMRT Indications (single-option logic)

    IMRT is medically necessary when at least ONE of the following clinical indications is met:

    Pediatric: Any solid tumor in a patient under 18 years of age; IMRT is standard to minimize dose to developing tissues.age<18
    CNS and Skull Base: Ocular tumors, skull base tumors, primary CNS tumors, spinal tumors requiring dose escalation near cord, craniospinal irradiation.
    Head and Neck: All primary and secondary head and neck cancers requiring definitive, adjuvant, or palliative radiation, including nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, hypopharynx, larynx, thyroid, salivary glands, mucosal melanoma, and cutaneous disease with perineural/cranial nerve invasion.
    Breast: Left-sided breast cancer where cardiac constraints (Heart V25 >10% or LAD mean dose >15 Gy) cannot be met with 3D conformal planning; internal mammary node irradiation in selected high-risk nodal disease; APBI via IMRT; reirradiation; bilateral nodal irradiation; arms-down positioning limiting 3D approaches.Heart V25>10% or LAD mean>15Gy
    Thoracic: Primary/secondary mediastinal tumors, early-stage NSCLC when SBRT not feasible, esophageal cancer, Stage III NSCLC when 3D-CRT cannot meet lung constraints (documented V20 >30% and IMRT reduces V20 by ≥10% while maintaining V5 <65%).documented V20>30% with 3D planning and IMRT reduces V20 by >=10% and maintains V5<65%
    Abdominal/Pelvic: HCC, intrahepatic cholangiocarcinoma, pancreatic, gastric, cervical with para-aortic involvement, endometrial with para-aortic nodes, bladder requiring boost, prostate for hypofractionation.
    Sarcoma/Lymphoma/Reirradiation: Retroperitoneal sarcoma, desmoid, extremity STS near neurovascular structures; mediastinal lymphoma when IMRT reduces cardiac/pulmonary dose; any reirradiation where cumulative dose would exceed tolerances without IMRT dose-sculpting.

    inv-07: SRS/SBRT Intracranial/Spinal Coverage

    Covered when the patient has ONE of the listed conditions AND meets the performance status criteria below:

    Brain metastases 1-4: SRS preferred over WBRT for patients with KPS ≥70; dose standards by lesion size (e.g., <2 cm: 20–24 Gy x1; 2–3 cm: 18 Gy x1; 3–4 cm: 15 Gy x1); resection cavity SRS dosing examples provided.KPS>=70
    Brain metastases >4: SRS to individual lesions covered when total tumor volume and patient status appropriate (KPS ≥60); HA-WBRT is an alternative.KPS>=60
    Post-resection cavity: SRS preferred over WBRT for 1–2 resection cavities.
    Primary CNS malignancies: SRS as boost or salvage for lesions <5 cm with adequate performance status.lesion<5cm
    Spinal metastases (SBRT): Covered for KPS ≥60 or ECOG ≤2, no epidural compression requiring surgery, controlled/oligoprogressive systemic disease; dose standards provided.KPS>=60 or ECOG<=2
    Performance Status Requirement: Mandatory: KPS ≥40 OR ECOG ≤3 at treatment initiation; for patients expected to recover, expected KPS ≥70 or ECOG ≤2 within a clinically reasonable timeframe.KPS>=40 or ECOG<=3

    inv-08: SBRT Extracranial Indications

    Coverage is met when the patient has ONE of the following extracranial indications (all ages unless specified):

    Early-stage NSCLC (medically inoperable): T1–T3 N0 M0 medically inoperable due to FEV1 <50% predicted and/or DLCO <50% predicted, cardiac comorbidity, or other contraindication to surgery; peripheral, central, and ultra-central dosing regimens specified.FEV1<50% and/or DLCO<50%
    Early-stage NSCLC (operable but high risk): SBRT may be used as an alternative for operable patients at high operative risk after multidisciplinary discussion; tissue biopsy strongly recommended.
    Prostate localized: Ultra-hypofractionated SBRT (36.25 Gy in 5 fractions) for low- to intermediate-risk; requires IMRT planning, IGRT every fraction, fiducials or equivalent, rectal spacer if appropriate, and documented informed consent regarding options/risks.
    Liver HCC: Unresectable, not amenable to ablation, Child-Pugh A or B7, ≤3 lesions, total tumor volume compatible with safe dosing (per CMS LCD L35076).Child-Pugh A or B7; <=3 lesions
    Oligometastatic disease: 1–5 measurable metastases with controlled primary, ECOG 0–2, curative or consolidative intent documented; eligible histologies listed (breast, colorectal, melanoma, NSCLC, prostate, RCC, sarcoma).1-5 lesions; ECOG 0-2
    Reirradiation of previously irradiated pelvic, head and neck, or other sites with stereotactic precision when required to respect cumulative dose; prior RT records required.

    inv-09: Proton Beam Therapy Group 1 Indications

    PBT is medically necessary when the clinical indication meets Group 1 criteria OR meets Group 2 with evidence development; at least ONE of three core criteria (A,B,C) must be documented.

    Core criteria requirement: At least one ASTRO core criterion must be documented: A) Proximity to critical structure requiring steep dose gradient; B) Integral dose reduction compared to best achievable photon plan; or C) Reirradiation where cumulative tolerance would be exceeded without proton dose-sculpting.
    Pediatric patients: All malignant or benign tumors in patients under 18 with curative intent are covered without additional comparative dosimetry when one of Criteria A, B, or C is met.age<18
    CNS/Skull base indications: Unresectable benign or malignant CNS tumors, ocular tumors, skull base tumors, spinal cord tumors where cord tolerance may be exceeded with photons, and craniospinal irradiation.
    Head and Neck (adults): Nasopharynx, nasal cavity, paranasal sinuses, and advanced/unresectable head and neck cancers where proximity to optic apparatus, brainstem, spinal cord, mandible, or salivary glands requires proton precision.
    Thoracic/mediastinal: Esophageal cancer when PBT achieves dosimetric superiority over photon IMRT; mediastinal tumors including thymoma, mediastinal lymphoma, malignant pleural mesothelioma where proton reduces lung/cardiac dose.
    Abdominal/Pelvic: HCC and intrahepatic cholangiocarcinoma unresectable with curative intent; unresectable retroperitoneal sarcomas; advanced pelvic tumors where proton reduces bowel/bone marrow dose.

    inv-10: Group 1: Frequently Supports PBT (Medically Necessary)

    Covered when ANY of the following Group 1 criteria are met

    Pediatric and hereditary: Patients under 18: all malignant or benign tumors with curative intent; patients with hereditary cancer predisposition syndromes (e.g., NF-1, Li-Fraumeni, ATM, retinoblastoma, BRCA1/2, Lynch) where volume minimization is paramount. No additional comparative dosimetry required when one of Criteria A,B,C is met.age<18 or documented syndrome
    CNS and skull base indications: Unresectable benign or malignant CNS tumors (e.g., astrocytoma, GBM, medulloblastoma, acoustic neuroma, craniopharyngioma), ocular tumors, skull base tumors (chordoma, chondrosarcoma), craniospinal irradiation, and spine/spinal cord tumors where photon therapy would exceed cord tolerance or prior irradiation exists.anatomic/diagnostic
    Head and neck (adults): Nasopharynx, nasal cavity, paranasal sinuses, and other accessory sinus tumors; advanced/unresectable head & neck cancers with proximity to critical structures requiring proton precision.age>=18 and anatomic/clinical
    Thoracic: Primary esophageal cancer when proton achieves dosimetric superiority; mediastinal tumors including thymoma, mediastinal lymphoma, thoracic sarcomas, and malignant pleural mesothelioma where PBT reduces cardiac/lung dose.dosimetric superiority or anatomy
    Abdominal/pelvic: HCC and intrahepatic cholangiocarcinoma (unresectable, non-metastatic, curative hypofractionated regimens), unresectable retroperitoneal sarcomas, and advanced pelvic tumors with extensive nodal disease where proton reduces normal tissue dose.anatomic/clinical
    Skeletal and re-irradiation: Primary bone tumors of any site and any re-irradiation case where prior dose dictates the need for proton precision (Z92.3 required; prior RT records documented).prior RT documented
    Pituitary neoplasm: Pituitary tumors requiring radiation where proton achieves superior dose distribution.anatomic/clinical
    Prostate (adult): Non-metastatic prostate cancer when documented dosimetric advantage over photon therapy is demonstrated and required documentation (CT/MRI staging, DVH, informed discussion) is provided.adult and documented dosimetric advantage

    Additional documentation required as listed in Section 4D.1

    inv-11: Group 2: Coverage with Evidence Development (CED)

    Covered when ALL of the following are met

    CED enrollment: Patient is enrolled in an IRB-approved clinical trial or multi-institutional registry with prospective data collection (enrollment documented).enrollment documented

    Required for all Group 2 indications.

    Listed Group 2 conditions: Other head & neck cancers not in Group 1; selected breast cancer per ASTRO criteria; early-stage lung when photon cannot meet constraints; locally advanced lung (Stage III NSCLC); pancreatic cancer with dosimetric superiority; renal/adrenal metastases; oligometastatic liver lesions with curative intent; certain adult pelvic malignancies; anal canal cancer; lymphoma outside Group 1. Direct patient-specific isodose comparison between proton and best achievable IMRT plan is required for all Group 2 cases.indication-specific

    Direct patient-specific isodose comparison required; see Proton Beam Documentation.

    inv-12: IGRT Coverage Criteria

    IGRT professional component (77387-26) covered when ALL of the following are met

    IGRT documentation and review: The radiation oncologist personally reviews localization images and documents the review in the daily or weekly clinical note; treatment requires daily or weekly image-based target localization to ensure accuracy; billing frequency follows weekly for standard EBRT and daily for boost, brachytherapy, and SBRT.documentation and clinical need

    Technical IGRT components are bundled into delivery codes; only 77387-26 is separately reportable for professional review/interpretation.

    inv-13: SRT — Medical Necessity (Meets Criteria)

    SRT meets medical necessity when ALL of the following are documented:

    Primary conditions: 1) Histologically confirmed basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC); 2) Tumor is a primary (not recurrent) non-melanoma skin cancer; 3) Tumor diameter ≤4 cm; 4) Tumor depth ≤6 mm; 5) Tumor does NOT have aggressive morphology (morpheaform, infiltrative, micronodular BCC; desmoplastic cSCC); 6) No perineural or perivascular invasion; 7) Tumor is NOT a very high-risk SCC per NCCN criteria; AND 8) At least ONE of: (a) patient is not a surgical candidate with documented reason, (b) patient declines surgery after informed consent, (c) tumor in anatomically sensitive location where surgery would compromise function/cosmesis, (d) multiple simultaneous NMSCs in same important area.

    Based on ASTRO guideline and CMS LCD L40179; supporting documentation (pathology, tumor size/depth, photos, reasons surgery not pursued) required.

    inv-14: SRT — Dose and Fractionation Recommendations (Guidance)

    Definitive RT dose-fractionation examples per ASTRO guideline (informational for prescribing):

    Dose-fractionation: Examples: Conventional fractionation 180–200 cGy/fx (definitive BED10 70–93.5); Hypofractionation 210–500 cGy/fx (BED10 56–88); Typical SRT regimens 12–20 fractions; standard examples: 5000 cGy in 20 fx, 5400 cGy in 18 fx, 4500 cGy in 15 fx.

    Informational dosing examples from ASTRO guideline.

    inv-15: Postoperative and Regional Nodal RT Indications

    Per ASTRO guideline, postoperative and nodal RT indications and dose ranges:

    Strong postoperative indications for cSCC: Gross perineural spread, close or positive margins not correctable with further surgery, recurrence after prior margin-negative resection, T3–T4 tumors, desmoplastic or infiltrative tumors in immunocompromised patients.

    Strong recommendations per ASTRO.

    Conditional postoperative indications for BCC: Close or positive margins not correctable with further surgery, recurrence after prior margin-negative resection, locally advanced tumors involving bone or infiltrating muscle.

    Conditional recommendations.

    Regional nodal RT: After therapeutic lymphadenectomy: 6000–6600 cGy conventional fractionation. Elective nodal RT for cSCC with thickness >6 mm: 5000–5400 cGy conventional fractionation.

    Dose ranges per ASTRO.

    inv-16: SBRT/SRS - Not Medically Necessary Conditions

    SBRT is not covered in the following circumstances:

    SBRT_exclusions: SBRT used as a boost following a full conventional RT course; any SBRT course exceeding 5 fractions (courses >5 fractions must be coded as IMRT or conventional EBRT); primary treatment of bone, breast, uterus, or ovary without documented justification referenced to CMS LCD L35076; SRS for patients with >10 brain metastases or rapidly progressing systemic disease with limited life expectancy; cobalt-60 pallidotomy; SBRT when conventional RT is appropriate without documented dosimetric/clinical rationale; separate billing of 77387-26 with 77373 on same date of service (image guidance is bundled).

    Enumerated denial conditions per Section 5C.

    inv-17: Proton beam therapy - Not Medically Necessary Conditions

    Proton beam therapy is not covered for the following adult indications unless trial enrollment meeting Group 2 CED criteria or patient-specific dosimetric superiority is provided:

    Proton_adult_exclusions: Breast cancer; esophageal cancer without proton-specific dosimetric advantage; gastric cancer; gynecologic cancers absent exceptional circumstances; lung cancers in adults absent qualifying trial enrollment; lymphoma absent mediastinal proximity criteria or trial enrollment; pancreatic cancer absent trial enrollment; prostate cancer when comparative dosimetry does not show superiority or required documentation is absent.

    Adult-specific non-coverage list.

    Proton_allages_exclusions: Any case failing to meet at least one ASTRO Core Criterion A/B/C; Group 2 indications without qualifying trial/registry enrollment; absence of required patient-specific comparative dosimetry when indicated; proton therapy as investigational arm only of a trial not covered under standard policy.

    Cross-age non-coverage and documentation triggers.

    inv-18: Brachytherapy - Not Medically Necessary Conditions

    Brachytherapy is not covered in these situations:

    Brachy_exclusions: Electronic brachytherapy devices (e.g., Xoft/Axxent) for any indication are not medically necessary; brachytherapy for systemic or diffuse disease; combined EBRT + brachy boost for intermediate-risk prostate cancer without individualized rationale; postoperative brachytherapy for low-risk Stage IA Grade 1–2 endometrial cancer without myometrial invasion.

    Enumerated brachytherapy non-coverage conditions.

    inv-19: SRT - Not Medically Necessary Conditions

    SRT is not covered in the following circumstances and will be denied:

    SRT_exclusions: Use of deleted code 77401 for DOS on/after 1/1/2026; billing standard EBRT planning or management codes for SRT services; 77439 billed more than once per treatment course or without corresponding primary SRT delivery code (77437 or 77438); HRDUS guidance billed as image guidance for daily SRT delivery; electronic brachytherapy billed under SRT codes; SRT for non-cutaneous malignancies; SRT for patients with radiosensitivity syndromes; SRT as primary treatment for patients <60 who are surgical candidates without individualized justification.

    SRT-specific billing and clinical exclusions per Section 5F.

    inv-20: FLASH - Investigational

    FLASH (0747T) is investigational and not covered as standard clinical service.

    FLASH_investigational: 0747T (FLASH radiation therapy) is investigational; routine clinical use is not supported by current guidelines and is not covered except as part of an approved clinical trial under Section 7.

    Investigational stance.

    inv-21: General coverage stance

    Policy stance and expectations

    Documentation & best practices: Curative recommends documentation of tobacco use status and smoking cessation counseling/referral as part of every radiation therapy plan; clinical documentation should follow CMS LCD standards adopted by the policy (diagnosis, stage, performance status, radiation prescription, imaging, and modality justification). Coverage determinations remain subject to member benefit plan limits and applicable federal/state rules (e.g., ACA EHB, No Surprises Act continuity provisions).

    Best-practice recommendations; not prerequisites for authorization but strongly encouraged.

    The inclusion of a service, procedure, or CPT/HCPCS code in this policy does not guarantee coverage. Coverage decisions are determined by the terms, conditions, limitations, and exclusions of the member's specific benefit plan and certificate of coverage; this document provides criteria for medical necessity determinations only. Providers should verify member-specific benefits and plan limits prior to rendering or billing services.

    Several legacy CPT and HCPCS codes were deleted effective January 1, 2026 and are no longer applicable for dates of service on or after that date. Examples include: 77385, 77386, 77401, 77417, 77014 and HCPCS G-codes G6001–G6017. Claims submitted with these deleted codes for DOS on/after 2026-01-01 will be denied.

    By definition in this policy, SBRT/SRS is a short-course stereotactic treatment delivered in 1 to 5 fractions. Any treatment course that exceeds 5 fractions does not qualify as SBRT and must be reported and coded as IMRT or conventional EBRT using the appropriate 2026 complexity-based delivery codes.

    Deleted CPTs and HCPCS used prior to 2026 must not be billed for dates of service on or after January 1, 2026. Specifically, CPT 77401 (superficial/orthovoltage delivery), the IGRT G‑codes (G6001–G6017), and CPT 77014 (CT guidance) are deleted and must not be submitted for DOS ≥ 2026‑01‑01. Use the new 2026 SRT codes (77436–77439) and report the IGRT professional component as 77387‑26 where appropriate.

    Certain clinical scenarios do not meet the medical necessity criteria for stereotactic radiation (SRT/SBRT) as primary therapy. For example, SRT used as first‑line treatment in patients who are surgical candidates without documented contraindication or anatomically sensitive rationale is not supported. All radiation therapy requests must still meet the core medical necessity standard, including a confirmed diagnosis, documented performance status, complete physician‑signed radiation prescription, and justification of modality appropriateness.

    The policy identifies multiple modality‑specific exclusions and billing rules. Examples include denial of SBRT when used as a boost after a full conventional RT course, SBRT courses >5 fractions, electronic brachytherapy for skin cancers, numerous adult proton indications absent trial enrollment or demonstrated dosimetric superiority, and SRT billing or clinical scenarios using deleted codes or inappropriate planning/management codes. Refer to the modality sections for complete lists of exclusions and billing constraints.

    For fully insured individual and small group plans subject to the ACA Essential Health Benefits, there are no annual or lifetime dollar limits applicable to EHB services. This federal requirement applies to covered radiation therapy services where the member's plan is governed by EHB rules.

    Coverage determinations in this policy reflect medical necessity criteria only. They do not address every contractual exclusion or benefit limitation. Final coverage for any claim remains subject to the member's specific benefit plan, certificate of coverage, and any applicable state or federal regulatory requirements.

    For Stage III non‑small cell lung cancer treated with concurrent chemoradiotherapy, the policy specifies a standard regimen of 60 Gy in 30 fractions. Dose escalation beyond 60 Gy is not supported by evidence and is considered not medically necessary.

    Postoperative vaginal cuff brachytherapy following hysterectomy is not indicated for certain very low‑risk endometrial cancers. Specifically, postoperative brachytherapy is not recommended for low‑risk Stage IA, Grade 1–2 endometrial cancer without myometrial invasion.

    The policy lists several specific items considered not medically necessary, including high‑resolution dermal ultrasound (HRDUS) guidance for daily dose adjustment during SRT, electronic brachytherapy (EBT) for non‑melanoma skin cancers, and other modality‑specific practices lacking sufficient evidence or excluded by CMS LCDs. These items will not be authorized or reimbursed when billed as standard clinical services.

    To summarize modality‑specific noncoverage examples: SBRT used as a boost to a full conventional RT course, SBRT courses >5 fractions, adult proton indications absent trial enrollment or dosimetric superiority, electronic brachytherapy across indications, SRT billed with deleted codes or inappropriate planning/management codes, and FLASH therapy (0747T) as investigational are all explicitly identified as not medically necessary or not covered under routine policy provisions.

    Certain sections of the document adopt CMS LCD clinical documentation standards and federal requirements but do not in themselves list additional explicit 'Not Medically Necessary' interventions beyond those enumerated in the modality sections. Users should consult the specific modality sections and CMS LCD references for explicit exclusion lists.

    CPT/HCPCS and Diagnosis Codes

    Treatment Planning CPT CodesCPT
    77261Therapeutic radiology treatment planning; simple
    77262Therapeutic radiology treatment planning; complex
    77263Therapeutic radiology treatment planning; intermediate
    77280Simulation-aided field setting; simple
    77285Simulation-aided field setting; intermediate
    77290Simulation-aided field setting; complex
    77293Respiratory motion management simulation
    77299Unlisted procedure, therapeutic radiology treatment planning
    77300Basic radiation dosimetry calculation, each
    77301Intensity modulated radiotherapy (IMRT), planning, including computer-generated dose volumetric histogram
    1–10 of 13
    1/2
    Treatment Management CPT CodesCPT
    77331Special dosimetry, each field
    77334Treatment devices, design and construction; simple
    77336Continuing medical physics consultation (per 5 treatments)
    77336Continuing medical physics consultation (per 5 treatments)
    77427Radiation treatment management, per 5 fractions (or weekly if receiving daily)
    77432Stereotactic radiation treatment management of cranial lesion(s) (complete course)
    77469Intraoperative radiation treatment management
    77470Special treatment procedure (list in addition to code for primary procedure)
    External Beam Radiation Delivery (2026 complexity-based codes)CPTCovered
    77373Stereotactic body radiation therapy, treatment delivery, per fraction to 5 fractions total
    77387-26Guidance for localization of target volume for delivery of radiation treatment delivery - Professional Component Only
    77399Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services
    77402Level 1 - Simple: Single electron field, multiple non-abutting electron fields, or 2D photon treatment
    77407Level 2 - Intermediate: Single isocenter 3D-CRT or IMRT, NO active motion management
    77412Level 3 - Complex: Requires ANY ONE of active motion management, multiple isocenters, mixed photon-electron modality, or total skin electron therapy
    77424Intraoperative radiation treatment delivery, electrons
    77425Intraoperative radiation treatment delivery, photons
    Proton Beam Therapy CPT CodesCPT
    77520Proton treatment delivery; simple, without beam shaping
    77522Proton treatment delivery; simple, with beam shaping
    77523Proton treatment delivery; intermediate
    77525Proton treatment delivery; complex
    Brachytherapy CPT/HCPCS Codesmixed
    77750Infusion or instillation of radioelement solution
    77761Intracavitary radiation source application; simple
    77762Intracavitary radiation source application; intermediate
    77763Intracavitary radiation source application; complex
    77767Remote afterloading HDR radionuclide skin surface brachytherapy; lesion diameter up to 2.0 cm
    77768Remote afterloading HDR radionuclide skin surface brachytherapy; lesion diameter over 2.0 cm
    77770Remote afterloading HDR radionuclide intracavitary brachytherapy; 1 channel
    77771Remote afterloading HDR radionuclide intracavitary brachytherapy; 2-12 channels
    77772Remote afterloading HDR radionuclide intracavitary brachytherapy; more than 12 channels
    77778Interstitial radiation source application; complex
    1–10 of 13
    1/2
    Surface Radiation Therapy (SRT) CodesCPTCovered
    77436Surface radiation therapy; superficial treatment planning and simulation-aided field setting
    77437Surface radiation therapy; superficial, delivery, ≤150 kV, per fraction
    77438Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction
    77439Surface radiation therapy; add-on code billed once per treatment course (used with 77437 or 77438)
    Other Radiation Oncology Codesmixed
    0747TRadiation treatment delivery, ultra-high dose rate (FLASH), per fraction
    A9699Radiopharmaceutical, diagnostic, not otherwise classified
    G0339Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course or first session
    G0340Image-guided robotic linear accelerator-based stereotactic radiosurgery, fractionated treatment, per session, second through fifth sessions
    Deleted 2026 Codes - Do Not BillmixedNot Covered
    77385IMRT delivery, simple (DELETED 1/1/2026)
    77386IMRT delivery, complex (DELETED 1/1/2026)
    77401Radiation treatment delivery, superficial and/or orthovoltage (DELETED 1/1/2026)
    77417Therapeutic radiology port images (DELETED 1/1/2026)
    77014CT guidance for placement of radiation therapy fields (DELETED 1/1/2026)
    G6001Ultrasonic guidance for placement of radiation therapy fields (DELETED 1/1/2026)
    G6002Stereoscopic x-ray guidance for localization of target volume (DELETED 1/1/2026)
    G6003-G6016All G-codes for radiation therapy delivery (DELETED 1/1/2026)
    G6017Intra-fraction localization and tracking of target or patient motion (DELETED 1/1/2026)
    Treatment planning and management codes (expanded)CPT
    77261Treatment planning - simple
    77262Treatment planning - complex
    77263Treatment planning - intermediate
    77280Simulation - simple
    77285Simulation - intermediate
    77290Simulation - complex
    77293Respiratory motion management simulation
    77299Unlisted planning code
    77300Special dosimetry/plan
    77301IMRT planning
    1–10 of 26
    1/3
    EBRT delivery codesCPT
    77402EBRT delivery - Level 1 (simple)
    77407EBRT delivery - Level 2 (intermediate)
    77412EBRT delivery - Level 3 (complex)
    77387-26IMRT/complex delivery - professional component
    Deleted or obsolete codes (effective 2026-01-01)mixed
    77385Deleted
    77386Deleted
    77417Deleted
    77014Deleted
    77401Deleted (superficial/orthovoltage)
    G6001Deleted
    G6002Deleted
    G6003-G6016Deleted
    G6017Deleted
    Surface Radiation Therapy (SRT) specific codesCPT
    77436SRT planning/simulation
    77336Physics consultation for SRT (alternate usage noted)
    SRT delivery codes referencedCPT
    77437SRT delivery (per Section 4G reference)
    77438SRT delivery (per Section 4G reference)
    SBRT/SRS CPT and relatedmixed
    77373Stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) delivery
    77431Stereotactic body radiation therapy, per fraction
    77432Stereotactic body radiation therapy, per course (other related)
    G0339Image-guided robotic linear accelerator-based stereotactic radiosurgery (Medicare use)
    G0340Image-guided robotic linear accelerator-based stereotactic radiosurgery (Medicare use)
    77387-26Image guidance — professional component (note: image guidance bundled into SBRT codes; separate billing with 77373 is a billing error)
    IMRT coding (2026)CPT
    77407IMRT delivery Level 2 (single isocenter, no active motion management)
    77412IMRT delivery Level 3 (multiple isocenters or active motion management)
    77301IMRT planning
    Proton beam therapy CPT codesCPT
    77520Proton therapy planning/delivery (CPT group start)
    77522Proton therapy delivery (specific descriptor)
    77523Proton therapy related code
    77525Proton therapy related code
    Brachytherapy CPT/HCPCS (covered)mixedCovered
    77750Brachytherapy-related code
    77761Brachytherapy-related code
    77762Brachytherapy-related code
    77763Brachytherapy-related code
    77767Brachytherapy-related code
    77768Brachytherapy-related code
    77770Brachytherapy-related code
    77771Brachytherapy-related code
    77772Brachytherapy-related code
    77778LDR permanent seed implant (prostate)
    1–10 of 13
    1/2
    IGRT codingCPTCovered
    77387-26IGRT professional component
    Superficial Radiation Therapy (SRT) codes (expanded)CPTCovered
    77436SRT planning/simulation (new 2026)
    77437SRT delivery per fraction (new 2026)
    77438SRT delivery per fraction (new 2026)
    77439SRT add-on ultrasound guidance once per course (new 2026)
    77336Physics consultation per week of therapy (used with SRT)
    Intraoperative RT codes (referenced)CPT
    77424IORT electrons (mentioned for IORT coding reference)
    77425IORT photons (mentioned for IORT coding reference)
    Deleted codes (2026)mixedNot Covered
    G6001-G6017IGRT G-codes (deleted effective Jan 1, 2026)
    77014CT guidance for placement of RT fields (deleted)
    77401Superficial/orthovoltage delivery (deleted effective Jan 1, 2026)
    Covered SRT CPT Codes (2026)CPTCovered
    77436Surface radiation therapy; superficial treatment planning and simulation-aided field setting.
    77437Surface radiation therapy; superficial, delivery, ≤150 kV, per fraction (e.g., electronic brachytherapy).
    77438Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction.
    77439Surface radiation therapy; ultrasound guidance, add-on, billed once per course.
    77336Continuing medical physics consultation (applicable to SRT when licensed) per week of therapy.
    Deleted Codes (do not submit for dates of service on/after 2026-01-01)mixedNot Covered
    77385Deleted — replaced (use 77407/77412 as appropriate).
    77386Deleted — replaced (use 77407/77412 as appropriate).
    77401Deleted — superficial/orthovoltage delivery (must not be billed).
    77417Deleted — bundled; no replacement (use delivery code).
    77014Deleted — technical component bundled into delivery codes; professional component use 77387-26.
    G6001Deleted
    G6002Deleted
    G6003Deleted
    G6016Deleted
    G6017Deleted
    Other HCPCSHCPCS
    A9699Radiopharmaceutical, Diagnostic, NOS - covered when no specific HCPCS exists; requires documentation of agent, indication, and ordering physician credentials.
    SBRT Fraction CodesHCPCS
    G0339SBRT Delivery - first fraction (Medicare Advantage/Medicaid billing).
    G0340SBRT Delivery - fractions 2-5 (Medicare Advantage/Medicaid billing).
    Unlisted Codes Requiring Prior AuthorizationCPT
    77299Unlisted procedure - not covered without prior authorization.
    77399Unlisted procedure - not covered without prior authorization.
    77799Unlisted procedure - not covered without prior authorization.
    SBRT/SRS Codes and Bundling RulesCPT
    77373Stereotactic radiosurgery (SBRT) delivery — course definition and bundling rules apply.
    77387Image guidance (bundled into SBRT delivery; billing separately with 77373 is an error).
    SBRT/SRS delivery and image guidancemixed
    77373Stereotactic radiosurgery (SBRT) delivery
    G0339SBRT delivery, CPT-equivalent
    G0340SBRT delivery, CPT-equivalent
    77387Image guidance (IGRT) - note: bundled with SBRT delivery
    SRT codesCPT
    77401Deleted SRT code (do not use for DOS on/after 1/1/2026)
    77437Superficial radiation therapy delivery (SRT)
    77438Superficial radiation therapy delivery (SRT)
    77439SRT technical component - limited use (one per course)
    Brachytherapy codes (electronic brachytherapy excluded)CPT
    77767Remote afterloading HDR radionuclide skin surface brachytherapy; lesion diameter up to 2.0 cm
    77768Remote afterloading HDR radionuclide skin surface brachytherapy; lesion diameter over 2.0 cm
    77770Remote afterloading HDR radionuclide intracavitary brachytherapy; 1 channel
    77771Remote afterloading HDR radionuclide intracavitary brachytherapy; 2-12 channels
    77772Remote afterloading HDR radionuclide intracavitary brachytherapy; more than 12 channels
    77778Interstitial radiation source application; complex
    Investigational codeCPTExperimental
    0747TFLASH radiation therapy (investigational)
    Applicable ICD-10-CM diagnosis categoriesICD-10
    C00-C14Malignant neoplasms of lip, oral cavity, and pharynx
    C15Malignant neoplasm of esophagus
    C16Malignant neoplasm of stomach
    C17-C21Malignant neoplasms of small intestine, colon, rectosigmoid junction, rectum, anal canal
    C22Malignant neoplasm of liver and intrahepatic bile ducts
    C23-C26Malignant neoplasms of biliary tract, pancreas, other digestive organs
    C30-C32Malignant neoplasms of nasal cavity, middle ear, accessory sinuses, larynx
    C33-C34Malignant neoplasm of trachea, bronchus, and lung
    C37-C39Malignant neoplasms of thymus, heart, mediastinum
    C40-C41Malignant neoplasms of bone and articular cartilage
    1–10 of 35
    1/4
    Applicable ICD-10-CM Diagnosis CodesICD-10Covered
    C40-C41Malignant neoplasms of bone and articular cartilage.
    C43-C44Melanoma and other malignant neoplasms of skin.
    C44.0-C44.9Non-melanoma skin cancers (BCC, cSCC) - primary SRT indication.
    C45-C49Malignant neoplasms of mesothelial and soft tissue.
    C50Malignant neoplasm of breast.
    C51-C57Malignant neoplasms of female genital organs.
    C58Malignant neoplasm of placenta.
    C60-C63Malignant neoplasms of male genital organs.
    C64-C68Malignant neoplasms of urinary tract.
    C69Malignant neoplasm of eye and adnexa.
    1–10 of 26
    1/3
    Approximate distribution of EBRT complexity — Level distribution
    Level 1 (77402)Simple EBRT (single electron field, multiple non-abutting electron fields, or 2D photon treatment) — approximately <5% of EBRT cases
    Level 2 (77407)Intermediate EBRT (single isocenter 3D‑CRT or IMRT without active motion management) — the 'workhorse' code, ~>50% of EBRT cases
    Level 3 (77412)Complex EBRT requiring ANY ONE qualifying feature (active motion management, multiple isocenters, mixed photon‑electron modality, or TSET) — approximately ~35% of EBRT cases
    Supporting imaging recency — Imaging within 90 days of simulation
    Imaging windowSupporting diagnostic or staging imaging must be available within 90 days of the treatment‑planning simulation
    Acceptable documentationImaging reports or DICOMs demonstrating tumor extent/stage included in prior‑authorization or medical record
    Exception noteWhen biopsy or imaging is infeasible, equivalent clinical evidence must be documented in the record
    Weekly management billing interval — One unit per 5 fractions
    Billing interval for weekly management (77427)One unit per 5 fractions (or one unit per week if patient receives daily radiation therapy)
    Documentation requiredEach unit requires a documented radiation oncologist management visit covering tolerance assessment, imaging/port film review, and clinical status
    SRT exception77427 is not applicable to SRT; use SRT‑specific management codes as defined in Section 4G
    Heart V25 constraint — IMRT consideration for left‑sided breast cancer
    Heart V25 thresholdHeart V25 >10% (or LAD mean dose >15 Gy) is a trigger to consider IMRT for left‑sided breast cancer
    Clinical implicationIf 3D conformal planning cannot meet these cardiac constraints, IMRT is medically necessary to reduce cardiac dose
    DocumentationTreatment plan/DVHs must demonstrate inability of 3D planning to meet Heart V25/LAD constraints and IMRT expected benefit
    SBRT lung pulmonary function thresholds — FEV1/DLCO criteria
    FEV1 thresholdFEV1 <50% predicted supports SBRT as treatment option for medically inoperable early‑stage NSCLC
    DLCO thresholdDLCO <50% predicted also supports SBRT candidacy for medically inoperable early‑stage NSCLC
    Clinical contextSBRT indicated for T1‑T3 N0 M0 medically inoperable patients when pulmonary function or comorbidity precludes surgery
    Brachytherapy dose/selection thresholds — Example dosages
    Prostate LDR dosagesI‑125: 144–160 Gy; Pd‑103: 115–125 Gy for LDR permanent seed implants
    Prostate HDR regimensExample HDR monotherapy regimens include 13.5 Gy ×2; other acceptable regimens per ABS guidance (e.g., 9.5 Gy ×4; 6.5 Gy ×6)
    Cervical HDR exampleHDR intracavitary regimen: 7 Gy ×4 (to achieve combined EQD2 ≥85 Gy to HRCTV D90) in definitive locally advanced disease
    Maximum tumor diameter
    Maximum SRT tumor diameterTumor diameter must be ≤ 4 cm to meet SRT criteria for primary BCC/cSCC
    ContextApplies to definitive SRT eligibility for primary non‑melanoma skin cancers per ASTRO and CMS LCD L40179
    DocumentationTumor measurement must be recorded in the medical record (clinical measurement or imaging) for prior authorization
    Maximum tumor depth
    Maximum SRT tumor depthTumor depth must be ≤ 6 mm to meet SRT criteria for primary BCC/cSCC
    Dose deposition relevanceSRT deposits >90% of dose within the first 5–10 mm; depth limit aligns with intended depth of treatment
    Measurement requirementDepth must be documented (clinical or imaging) in the treatment record for coverage determination
    Maximum SBRT fractions
    SBRT fraction limitSBRT/SRS defined as delivery in 1–5 fractions; maximum allowed is ≤ 5 fractions per course
    Coding implicationCourses exceeding 5 fractions must be coded and billed as IMRT or conventional EBRT, not SBRT
    Evidence noteMany ablative regimens achieve BED >100 Gy delivered in 1–5 fractions per key SBRT trials
    Texas PA Gold Card threshold
    Texas PA Gold Card thresholdA provider achieves exemption when ≥90% prior‑authorization approval rate for a specific radiation therapy service over a 12‑month evaluation period
    ApplicabilityApplies to fully insured and level‑funded plans in Texas only; annual reporting and rescission rules apply
    Rescission timingExemptions may be rescinded only in January and require physician‑level review for rescission decisions

    Provider Requirements, Prior Authorization, and Billing Rules

    Prior Authorization

    Prior authorization required

    Prior authorization (PA) is required for all CPT/HCPCS codes listed in Section 3 of this policy unless the member's benefit plan states otherwise.

    Prior Authorization

    Unlisted planning code (77299) requires review

    Unlisted planning code 77299 requires individual clinical review and written justification from the radiation oncologist explaining why no established code applies.

    • "Unlisted planning code (77299): Requires individual clinical review and written justification" (Section 4A/4A notes)
    Prior Authorization

    Prior authorization requires performance status and indication justification

    Prior authorization requests must include documented performance status and indication‑specific justification (e.g., oligometastatic intent, re‑irradiation rationale, prior RT records) as required by the applicable delivery or modality criteria.

    • Prior auth must document performance status (KPS/ECOG) where required and include indication‑specific rationale
    • For proton cases, identify which ASTRO Core Criterion (A, B, or C) is met
    Prior Authorization

    Proton beam therapy: Group 1 covered; Group 2 requires enrollment

    Proton beam therapy: Group 1 indications are covered when criteria are met; Group 2 indications require patient enrollment in an IRB‑approved clinical trial or multi‑institutional registry with prospective data collection for coverage.

    • Group 1: covered when core criteria met (pediatric, CNS, skull base, select adult indications)
    • Group 2: coverage conditional on documented enrollment in qualifying trial/registry
    Prior Authorization

    Advance authorization and documentation for unlisted/special codes

    Advance authorization is required for unlisted procedure codes (77299, 77399, 77799) with written clinical justification; HCPCS A9699 requires documentation of the specific agent and indication per policy.

    • 77299/77399/77799: not covered without advance authorization and written justification
    • A9699: requires documentation of specific agent, clinical indication, and ordering physician credentials
    Prior Authorization

    Proton therapy prior authorization: enrollment or dosimetric justification required

    Many adult proton therapy indications require prior authorization to confirm either enrollment in a qualifying trial/registry or submission of patient‑specific comparative dosimetry demonstrating dosimetric superiority over IMRT.

    • Proton therapy for many adult indications requires trial/registry enrollment or individual comparative dosimetry
    • Absence of required comparative dosimetry for Group 2 or outside Group 1 is grounds for denial
    Prior Authorization

    Prior authorization requirements vary by state; federal emergency exceptions apply

    Prior authorization requirements and processes vary by state; federal rules prohibit PA for emergency radiation therapy (e.g., malignant spinal cord compression). State laws may also affect PA timelines, exemptions, and reviewer qualifications.

    • State variations include Texas PA Gold Card, Maryland NCCN mandate, Indiana/Georgia step‑therapy prohibitions and PA response timelines
    • No PA may be required for emergency radiation (No Surprises Act/continuity of care protections)
    Note
    Note

    Full policy reference for prior authorization and documentation

    This callout consolidates provider actions and documentation expectations from the full policy where a specific chunk reference was not singularly assigned.

    • Refer to Section 4 Universal Prerequisites and Section 3 code list for full PA and documentation requirements
    Prior Authorization

    77470 special treatment procedure code: coverage requires documented complex circumstances

    Special treatment procedure code 77470 is payable only when one or more specified complex circumstances are documented (e.g., coordinated cytotoxic therapy timing, proton therapy, TBI, pediatric anesthesia, reconstruction of prior plan).

    • 77470 is covered in addition to primary RT delivery when listed special circumstances apply and are documented
    Note

    No step therapy sequencing specified in excerpt

    No step therapy sequencing requirements are specified in these policy excerpts; step therapy is not generally applied in this policy text.

    Prior Authorization

    Prostate PBT requires documented dosimetric advantage and informed‑consent discussion

    For prostate proton therapy (adult patients), prior authorization must include documentation of a documented dosimetric advantage over photon therapy and that the patient was informed of alternative photon, brachytherapy, surgery, and surveillance options.

    • Required: CT/MRI confirming T/N stage; DVH demonstrating critical structure protection; documented informed discussion of options
    Prior Authorization

    Complexity/step‑down: use lowest complexity that achieves dosimetric goals; document 77412 qualifiers

    When lower complexity planning (Level 1) achieves equivalent dosimetric goals, higher complexity levels (Level 2/3) are not medically necessary; IMRT/Level 3 (77412) requires explicit documentation of qualifying complexity factors or risk of downcoding exists.

    • If Level 1 achieves equivalent goals, higher complexity is not necessary
    • 77412 requires explicit documentation of qualifying factor (e.g., "Multiple isocenters utilized" or "Active motion management (Gating/SGRT) employed")
    Prior Authorization

    Maryland: mandatory step therapy override for stage IV cancer per NCCN

    In Maryland, step therapy override must be granted for stage IV cancer patients when the prescribed radiation therapy is indicated by NCCN Category 1 or 2A guidelines; denials must include specific clinical rationale beyond non‑NCCN compliance.

    • Maryland Insurance Code § 15‑142 mandates step therapy overrides for stage IV cancer per NCCN guidance
    • Utilization management staff must recognize NCCN Category 1/2A as mandatory grounds for override
    Prior Authorization

    Step therapy prohibitions for advanced/metastatic cancer — state law considerations

    Several states in Curative's footprint prohibit step therapy for stage IV/metastatic cancer or require acceptance of NCCN‑recommended treatments (examples: TX, GA, IN, MD); applying step therapy where prohibited risks regulatory noncompliance and denial.

    • Texas, Georgia, Indiana, and Maryland include statutory or regulatory prohibitions or mandates related to step therapy for stage IV/metastatic cancer
    • Providers should document NCCN‑based indications to support overrides where state law requires
    Note

    Regulatory references for prior authorization and step therapy

    State statutes, regulatory bulletins, and PA reform materials cited in the policy (e.g., Texas TDI, GA OCI Bulletin, DC Law 25‑100, Indiana HB 1114, Maryland Ins. Code) inform prior authorization and step therapy obligations and timelines for providers.

    • Policy references multiple state laws and regulatory materials that affect PA timelines and step therapy (see Revision History and Section 7)
    Documentation Required

    Required clinical documentation for prior authorization

    All radiation therapy requests must include: confirmed diagnosis, documented performance status (KPS or ECOG), clinical staging with supporting imaging, and a complete physician‑signed radiation prescription meeting the Universal Prerequisites.

    • Radiation prescription must include diagnosis with ICD‑10, clinical stage, treatment intent, target volumes (GTV/CTV/PTV), dose prescription, fractions, and modality
    • Supporting imaging should be within 90 days of simulation when applicable
    Documentation Required

    Maintain a complete physician‑signed radiation prescription

    Providers must maintain a physician‑signed radiation prescription that includes diagnosis with ICD‑10 code(s), stage, explicit treatment intent, target volumes, modality, boost details, dose prescription (total dose, dose per fraction, total fractions), dosimetry type, special parameters/justifications, physics consultation need, concurrent systemic therapy, and OAR dose constraints.

    • Prescription must be physician‑signed and include all elements listed in Universal Prerequisites (Section 4)
    Documentation Required

    IMRT documentation: explicit modality, inverse planning, DVH and signed verification

    IMRT claims must have documentation explicitly stating the modality is IMRT and that inverse planning was used; the record must include dose constraints for targets and OARs, radiation oncologist signature on isodose distributions and DVHs with date, beam/arc descriptions, and dosimetric verification signed by both radiation oncologist and medical physicist.

    • Explicit statements required: "IMRT" and "Inverse planning used"
    • Dosimetric verification and signatures with credentials and dates are required
    Documentation Required

    SBRT documentation: performance status, RO evaluation, re‑irradiation and oligometastatic justification

    For SBRT prior authorization and claims, document KPS or ECOG score, radiation oncologist evaluation with clinical and technical aspects, oligometastatic justification when applicable, prior RT records for re‑irradiation, and histologic confirmation or MDT rationale for lung SBRT when biopsy is omitted.

    • KPS/ECOG mandatory for SBRT
    • Prior RT records (dates, fields, doses) required for re‑irradiation; histology preferred for lung SBRT
    Documentation Required

    PBT documentation: ASTRO Core Criterion, DVH, independent verification, comparative dosimetry when required

    Proton beam therapy requests must document which ASTRO Core Criterion (A, B, or C) is met, include the treatment prescription with dose‑volume parameters and signed DVHs, patient setup verification methodology, independent dose calculation or measurement verification, and — for cases outside Group 1 — a direct patient‑specific isodose comparison between the proton and best achievable IMRT plan.

    • Identify ASTRO Core Criterion met (A, B, or C)
    • Submit signed DVHs, independent dose calculation, and patient‑specific proton vs IMRT isodose comparison for non‑Group 1 cases
    Denial Risk

    Proton therapy denial risk: missing enrollment or comparative dosimetry

    Proton beam therapy prior authorization will be denied if required trial/registry enrollment or patient‑specific comparative dosimetry is not submitted for Group 2 indications or for Group 1 exceptions that require dosimetric proof.

    • Absence of enrollment or comparative dosimetry is grounds for denial
    • Ensure enrollment documentation or comparative DVH/isodose files are included with the PA request
    Denial Risk

    Do not submit deleted codes for DOS on/after 2026‑01‑01 — will be denied

    When submitting claims, do not bill deleted CPT/HCPCS codes for dates of service on or after January 1, 2026 (including 77401, 77385/77386, 77014, G6001–G6017); such claims will be denied—use the 2026 replacement codes.

    • 77401 → use 77437 or 77438 for SRT delivery
    • 77385/77386 → use 77407 or 77412 as appropriate
    • 77014 and IGRT G‑codes technical components are bundled into delivery codes; use 77387‑26 for professional component
    Denial Risk

    IMRT downcoding risk if 77412 qualifying language is missing

    Lack of explicit qualifying documentation (e.g., "Multiple isocenters utilized" or "Active motion management (Gating/SGRT) employed") risks auditors downcoding a 77412 (Level 3) claim to 77407 (Level 2) or denying higher complexity coding.

    • Include explicit qualifying phrases in the clinical record to support 77412
    • Absence of these statements is grounds for downcoding
    Billing Rule

    SBRT image guidance bundling — do not bill 77387‑26 with 77373 on same DOS

    Separately billing the IGRT professional component (77387‑26) with SBRT delivery code 77373 on the same date of service is a billing error and may be denied; image guidance is bundled into SBRT delivery codes.

    • Do not bill 77387‑26 separately with 77373 on same DOS for SBRT
    • G0339/G0340 follow same bundling rules for Medicare Advantage/Medicaid billing
    Denial Risk

    SBRT boost billing will be denied — SBRT is a standalone course

    SBRT codes billed as a boost in addition to a full conventional RT course (i.e., 77373, G0339/G0340 used as a boost) will be denied as SBRT; SBRT is considered a standalone course.

    • Do not bill SBRT delivery codes as a boost following full conventional RT
    • SBRT must be a complete standalone course ≤5 fractions
    Billing Rule

    77439 ultrasound add‑on: single per course billing and documentation required

    SBRT technical add‑on 77439 (ultrasound guidance) is billed once per course and requires documentation of ultrasound guidance at planning; billing 77439 more than once per course or without the primary SRT delivery code will be denied.

    • 77439 billed once per course only and must be accompanied by 77437 or 77438
    • Document ultrasound guidance performed at planning
    Documentation Required

    SRT documentation: pathology, measurements, photos, surgical rationale, prescription, and KX modifier

    SRT claims must include pathology confirming BCC or cSCC, tumor diameter and depth, baseline clinical photographs, documentation why surgery is not primary (nonsurgical candidacy or informed refusal), full radiation prescription, and KX modifier for 77437 when billing under CMS LCD L40179 where applicable.

    • Pathology report with histologic subtype and aggressive features
    • Tumor measurements and clinical photos
    • Document why surgery is not primary; include radiation prescription elements
    • Use KX modifier on 77437 under LCD L40179 when applicable
    Documentation Required

    Re‑irradiation documentation: prior RT records required; include Z92.3

    For re‑irradiation requests include prior radiation therapy records (dates, fields, total doses) and the diagnosis code Z92.3 (personal history of irradiation) in the documentation; absence may trigger denial.

    • Prior RT records are required and Z92.3 should be used to indicate re‑irradiation context
    Documentation Required

    Proton comparative dosimetry required for non‑Group 1 indications

    For proton therapy cases outside Group 1, submit a patient‑specific comparative isodose/dosimetry between the proton plan and the best achievable IMRT plan; absence of this comparative dosimetry is grounds for denial.

    • Direct patient‑specific isodose comparison required for all Group 2 cases and non‑Group 1 exceptions
    • Population or case‑control comparisons are not sufficient
    Documentation Required

    SBRT for specified primary sites requires documented justification per LCD L35076

    When SBRT is used as primary treatment for certain specified primary sites (bone, breast, uterine, ovarian), provide documented justification referencing CMS LCD L35076 or individualized clinical rationale; lacking this justification risks denial.

    • Provide site‑specific documented justification per LCD L35076 when SBRT used for primary bone, breast, uterine, or ovarian tumors
    Billing Rule

    Electronic brachytherapy not supported — do not bill under SRT codes

    Electronic brachytherapy billed under SRT codes is not supported by the policy; document device and modality and do not bill electronic brachytherapy under SRT codes.

    • Electronic brachytherapy (Xoft/Axxent) is not medically necessary and must not be billed under SRT codes
    Documentation Required

    Radiation prescription must include all Universal Prerequisite elements and be physician‑signed

    The radiation prescription must include the complete set of elements enumerated in Universal Prerequisites (diagnosis ICD‑10, stage, intent, target volumes, modality, boost details, total dose, dose per fraction, total fractions, dosimetry type, OAR constraints) and be signed by the physician.

    • Prescription elements a–j per Universal Prerequisites must be present and physician‑signed
    Denial Risk

    Align documentation to CMS LCD standards — failure may prompt denial

    If required CMS LCD clinical documentation standards (referenced LCDs: L39553, L35076, L36658, L40179) are not met, Curative may deny the request or request additional information; providers should align documentation to these LCD standards.

    • Curative adopts CMS LCD documentation standards as benchmarks; failure to meet them may prompt denial or requests for additional documentation
    Note
    Note
    Note

    Coverage is subject to member benefit plan limits

    Coverage determinations in this policy reflect medical necessity only and remain subject to the member's specific benefit plan terms, limitations, and exclusions.

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background and Context

    Radiation therapy is used for diagnosis, staging, definitive or palliative treatment of malignant and selected benign conditions. Services must be delivered under the direction of a board‑certified radiation oncologist, supported by an evidence‑based treatment plan and complete physician‑signed radiation prescription. Coverage requires demonstration that services are reasonable and necessary per federal standards and consistent with national guidance (NCCN, ASTRO, ASCO) and applicable CMS LCDs.

    Core Medical Necessity Standard: services must be reasonable and necessary per 42 U.S.C. §1395y(a)(1)(A). Requests for radiation therapy must include a confirmed diagnosis (or equivalent clinical evidence), documented performance status, clinical staging with supporting imaging, a complete physician‑signed radiation prescription meeting the policy's Universal Prerequisites, and justification that the selected modality is clinically appropriate for the indicated condition.

    Complete Radiation Prescription — Physician‑signed elements required
    Required signatoryComplete radiation prescription must be a physician‑signed document
    Key elements (summary)Must include diagnosis with ICD‑10 code(s), clinical stage, explicit treatment intent, and anatomic target volumes (GTV, CTV, PTV as applicable)
    Supporting itemsPrescription should also reference planned modality, boost details, and relevant special parameters per Universal Prerequisites
    Radiation prescription — Detailed required elements
    Prescription content (detailed)Must state diagnosis and ICD‑10 code(s), clinical stage, explicit treatment intent (curative/adjuvant/palliative), target volume definitions (GTV/CTV/PTV), modality and boost details, total dose, dose per fraction, total number of fractions, dosimetry type (plan and DVH constraints), special treatment parameters and justification, need for physics consultation, concurrent systemic therapy, and organ‑at‑risk dose constraints
    Signature and datingPhysician signature and date required on the prescription and supporting isodose/DVH documentation
    Use in prior authorizationComplete prescription must be included in prior‑authorization submission or maintained in the medical record for audit
    Level 3 EBRT delivery definition — Qualifying conditions
    DefinitionLevel 3 EBRT (77412) requires documentation of ANY ONE qualifying condition: active motion management, multiple isocenters, mixed photon‑electron modality, or TSET
    Audit requirementClinical records must include explicit qualifying phrases (e.g., 'Multiple isocenters utilized' or 'Active motion management (Gating/SGRT) employed') or auditors may downcode to 77407
    Expected utilizationLevel 3 represents approximately ~35% of EBRT cases
    SBRT/SRS definition — 1–5 fraction stereotactic delivery
    DefinitionSBRT/SRS is stereotactic delivery in 1–5 fractions with high precision, image guidance, and immobilization; courses >5 fractions do not qualify
    Typical intent/doseAblative doses in 1–5 fractions commonly achieve BED >100 Gy in many regimens
    Billing noteImage guidance is bundled into SBRT delivery codes; do not bill 77387‑26 separately with 77373 on same DOS
    PBT core criteria — Three core reasons to support proton therapy
    Core Criterion AProximity to a critical structure requiring steep dose gradient to avoid exceeding OAR tolerance — supports PBT
    Core Criterion BMeaningful integral dose reduction compared to best achievable photon (IMRT) plan — supports PBT when patient‑specific dosimetry shows benefit
    Core Criterion CRe‑irradiation where cumulative dose to normal tissues would exceed tolerance without proton dose‑sculpting
    Pediatric indication — Pediatric PBT coverage without comparative dosimetry
    Pediatric coverageAll malignant or benign tumors in patients under 18 with curative intent are covered for PBT without requiring additional comparative dosimetry when one ASTRO core criterion (A/B/C) is met
    RationaleBragg peak physics reduces low‑dose scatter that harms developing tissues — pediatric advantage well established
    DocumentationStatement identifying which ASTRO core criterion is met and standard PBT documentation elements still required
    CED definition — Coverage conditional on trial/registry enrollment
    Definition of CEDCoverage with Evidence Development (CED) requires patient enrollment in an IRB‑approved clinical trial or multi‑institutional registry with prospective data collection
    ApplicabilityCED applies to Group 2 proton indications where standard evidence is insufficient; enrollment must be documented for coverage
    Comparative dosimetryFor Group 2 cases, direct patient‑specific isodose comparison between proton and best achievable IMRT plan is required in addition to enrollment
    77439 — Add‑on ultrasound guidance billing rule
    77439 usage77439 is an add‑on code for ultrasound guidance billed ONCE per SRT treatment course and may only be billed in conjunction with primary SRT delivery code (77437 or 77438)
    Billing constraint77439 may NOT be billed independently or more than once per course; KX modifier must be appended to 77437 when billing under LCD L40179 per CMS guidance
    DocumentationMedical record must document ultrasound guidance at planning/delivery when 77439 is billed
    Deleted code 77401 — Removed effective 2026‑01‑01
    Deleted codeCPT 77401 (superficial/orthovoltage delivery) is deleted effective 2026‑01‑01 and must NOT be billed for DOS on or after that date
    ReplacementUse new 2026 SRT codes 77436 (planning), 77437/77438 (delivery), and 77439 (ultrasound guidance add‑on) instead of 77401
    Operational noteSRT uses its own dedicated planning and management codes, not standard EBRT planning/management codes
    SBRT/SRS definition — Ablative doses in 1–5 fractions
    Typical BEDs and precisionSBRT/SRS delivers ablative doses in 1–5 fractions with sub‑millimeter precision and commonly achieves BED >100 Gy in many regimens
    Fractionation definitionBy policy definition SBRT/SRS is limited to 1–5 fractions; courses >5 fractions are not SBRT
    Clinical evidenceKey randomized and phase II trials (NRG/RTOG 0236, ORIOLE, COMET) support SBRT efficacy in selected indications
    Proton beam therapy definition — Bragg peak and established indications
    PBT physics advantageProton beam therapy exploits the Bragg peak to deposit the majority of dose at a defined depth with minimal exit dose, reducing integral dose to normal tissues
    Established indicationsClinical benefit best established for pediatric cancers, skull base tumors, ocular melanomas, and select re‑irradiation contexts
    Documentation requirementASTRO core criteria and patient‑specific dosimetry must be documented for coverage determination
    Surface Radiation Therapy (SRT) definition — Low‑energy x‑ray therapy
    SRT definitionSurface Radiation Therapy (SRT) uses low‑energy (50–500 kV) x‑rays depositing >90% of dose within first 5–10 mm and is appropriate for certain skin cancers (BCC, cSCC)
    Primary indicationSRT is intended for superficial lesions where surgery is contraindicated or would compromise cosmesis/function
    Depth relevanceDose deposition characteristics align with SRT depth limits (≤6 mm) used in coverage criteria
    Smoking cessation relevance — Clinical importance and documentation
    Clinical impact of cessationSmoking cessation during cancer treatment significantly improves survival and locoregional control; cessation should be documented and counseling/referral provided
    Supporting evidenceLarge cohort and head & neck studies show markedly improved outcomes for quitters versus continued smokers (e.g., 5‑yr OS differences in head & neck cancer)
    DocumentationTobacco use status and cessation counseling/referral should be recorded in the medical record per policy guidance

    Definitions and Code-Specific Notes

    C44.0-C44.9 — Non‑melanoma skin cancers as primary SRT indication
    Primary SRT diagnosis codesC44.0–C44.9 (non‑melanoma skin cancers: basal cell carcinoma and cutaneous squamous cell carcinoma)
    Use caseThese ICD‑10 codes denote primary indications for SRT when clinical criteria are met
    Documentation tipPathology confirmation and tumor measurements should accompany claims for SRT under these diagnosis codes
    G50.0 — Trigeminal neuralgia (SRS indication)
    Trigeminal neuralgia codeG50.0 — Trigeminal neuralgia (recognized SRS indication)
    ContextUsed to support SRS indication claims for functional radiosurgery procedures targeting trigeminal neuralgia
    DocumentationClinical neurologic assessment and prior conservative therapy documentation recommended for SRS requests
    Q28.2 — Arteriovenous malformation (SRS indication)
    AVM diagnosis codeQ28.2 — Arteriovenous malformation of cerebral vessels (recognized SRS indication)
    Clinical useSupports coverage of SRS for intracranial AVMs when performance status and lesion characteristics meet criteria
    DocumentationImaging (DSA/MRI/CT) and multidisciplinary rationale should be included with authorization requests
    Z92.3 — Personal history of irradiation required for re‑irradiation
    Re‑irradiation diagnosis codeZ92.3 — Personal history of irradiation; required when documenting re‑irradiation cases
    Documentation requirementPrior radiation records (dates, fields, total doses) must be provided for re‑irradiation and Z92.3 should be included in claims/authorization submissions
    Coverage implicationAbsence of prior RT documentation and Z92.3 may lead to denial for re‑irradiation or PBT Group 1/2 consideration

    Revision History and Document Changes

    2026-04-28Policy effective dateLatest

    Policy CUR-ONC-2026-001 becomes effective with Version 3.0 updating SRT, deleted codes, and CPT 2026 coding structure; includes addition of tobacco/smoking cessation section and SRT clinical criteria.

    2026-04-01Revision

    Version 2.0 revised to the 2026 CPT coding structure: deleted multiple legacy codes (77385, 77386, 77417, G6001–G6017, 77014), redefined EBRT delivery as complexity-based levels (77402, 77407, 77412), introduced SRT codes 77436–77439, and updated IGRT billing guidance (77387-26 professional component).

    2026-04-01Revision

    Version 1.0 initial policy creation incorporating NCCN 2025 guidelines, ASTRO 2024–2025 updates, ASTRO PBT Model Policy 2022, ABS 2025 HDR consensus, and relevant CMS LCDs and state laws.

    Policy metadata: Version 3.0, effective 2026‑04‑28. The document header indicates the current version and effective date for operational and reference purposes.

    Summary of material changes in this revision: the policy operationalizes the 2026 CPT/HCPCS coding updates including deletion of legacy IGRT G‑codes and CT guidance (77014), introduction of the SRT code set (77436–77439), and reorganization of EBRT delivery into complexity‑based codes (77402, 77407, 77412). Billing and bundling rules were updated (eg, IGRT technical components bundled into delivery codes, only 77387‑26 remains separately reportable for IGRT professional services; new SRT planning/delivery/add‑on guidance). Providers should follow the new code structure and the policy's billing rules for DOS on/after 2026‑01‑01.